



NDA 20498/S-025

SUPPLEMENT APPROVAL

AstraZeneca
Attention: Karen McCullough, Ph.D.
One MedImmune Way
Gaithersburg, MD 20878

Dear Dr. McCullough:

Please refer to your Supplemental New Drug Application (sNDA) dated July 16, 2014, received July 16, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Casodex® (bicalutamide) Tablets.

We acknowledge receipt of your amendments dated August 20; November 10, 14; December 2, 2014; January 9 and 29, 2015.

This “Prior Approval” supplemental new drug application provides for the following:

1. Renumbering of Section 2 Dosage and Administration
2. Updating Section 6 Adverse Reactions – Subsection 6.2 Post-Marketing Experience and Section 17 Patient Counseling Information to include updated information concerning photosensitivity as an adverse reaction.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.”

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Amy Tilley, Regulatory Project Manager, at 301-796-3994 or amy.tilley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.
Acting Division Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
02/27/2015